Lung Cancer Disease

Published Date : Jul 2023
Category : Chronic Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Lung Cancer is one of the most perilous and treacherous conditions that individuals are prevailing worldwide and has become a general medical problem. It is a significant global health issue, responsible for the highest number of cancer-related deaths worldwide. According to the American Cancer Society, approximately 80-85% of cases are classified as Non-Small Cell Lung Cancer (NSCLC), while Small Cell Lung Cancer (SCLC) accounts for 10-15% of cases.

Small cell lung carcinoma (SCLC) is an important revenue sector for lung cancer, according to Disease Landscape Insights. However, being less frequent than non-small cell lung cancer, SCLC poses specific challenges and opportunities for market players because of its lethal nature and swift growth. An extensive number of patients need specialized treatment choices and focused medicines, with a predicted incidence of about 57 per 100,000 people in the US. Small-cell carcinoma and low-grade carcinoma can be distinguished in a way that offers beneficial data for market segmentation and the development of products. Players in the market can develop creative solutions with Disease Landscape to meet the unique demands of this group of lung cancer patients by understanding the distinctive characteristics and frequency of SCLC.

Furthermore, Squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the three most prevalent kinds of non-small cell carcinoma. Adenocarcinomas tend to develop in individuals with non-smokers, contradicting a correlation of non-small cell lung carcinomas (NSCLCs) with tobacco exposure.

New Lung Cancer cases USA

The above graph provides historical data of new Lung Cancer cases in the US from 2013-2022. The overall incidence of lung cancer is increasing, leading to increased patient outcomes and quality of life. This shift in the lung cancer landscape presents substantial growth prospects for the treatment and diagnostics industry. The Disease Landscape Insights perspective reveals the advancing trends in lung cancer treatment and diagnostics shaping industry dynamics. Thus, changing the dynamics of lung cancer disease will drive the industry and will create market opportunities for different industry players.

Disease Landscape Insights investigates the thrilling journey into the realm of lung cancer care, where extraordinary developments and game-changing opportunities are restructuring the scenery.

Tobacco smoking, the leading avertible cause of death, contributes to up to 90% of lung cancer cases, with a projected increase in global cancer incidence, particularly in developing nations like BRICS. According to NIH in 2022, 1.9 million new cancer cases and 609,360 cancer deaths occurred in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death.

The below graph represents lung cancer mortality insights in the United States from 2013-2022.

Without strenuous global action, it is anticipated by the Lung Cancer Collaboration report that lung cancer deaths will rise by around 30% in the next decade, making it challenging for nations to achieve the 2030 Sustainable Development Goal (SDG) 3.4 target of reducing premature non-communicable disease mortality by one-third. To achieve this target, there is a lot to do not only from the government side but also from industry players.

Early detection of lung cancer is a contest, but significant advancements have been made in targeted treatments and combination therapies. These approaches influence molecular grouping and utilize the assortment of lung tumors, leading to higher outcomes for patients and providing prospects for the market players in the treatment and diagnostics industry to grow and create value.

Disease Landscape Insights empowers tactical decision-Making in the Diagnostic, Treatment, and Medical Device Landscape

Lung Cancer Diagnostic Analysis

Breaking Barriers, Saving Lives: Discover the Latest Market Developments & Market Insights with DiseaseLandscape!!

The diagnosis of lung cancer typically involves a combination of medical history evaluation, physical examination, imaging tests, and laboratory tests. The common steps and methods used in the diagnosis of lung cancer:

  1. Medical History and Physical Examination
  2. Imaging Tests:

Early detection of lung cancer has a considerable positive impact on 5-year survival, increasing it from less than 10% (stage four) to between 68% and 92% (stage one), and has the added financial benefit of lowering healthcare expenses.

Hence for early detection of Lung Cancer imaging tests play a vital role.

Imaging tests performed for Lung Cancer Diagnosis are-

  • Computed Tomography (CT) -

CT Scans are redefining Lung Cancer Detection. With their noteworthy ability to provide detailed images of the lungs, CT scans are instrumental in identifying lung nodules, tumors, and potential cancer spread. According to the American Lung Association, early detection through low-dose CT (LDCT) lung cancer screening has the power to modernize lung cancer survival rates, reducing mortality by an overwhelming 14-20%. By screening high-risk individuals, we can prevent over 12,000 lung cancer deaths.

  • Chest X-ray -

    A simple X-ray image of the chest may be the initial test performed to detect any abnormalities or doubtful areas in the lungs and according to WHO, 3.6 billion diagnostic X-rays are performed annually globally. In March 2022 plain radiography tests, including chest X-ray, were the most common, reporting for 90% of missed lung cancer cases, despite CT's greater sensitivity.
  • PET Scans -

    PET (Positron Emission Tomography) scans use a radioactive tracer to detect areas of high metabolic activity in the body. It can help determine if the cancer has spread to other parts of the body. PET scans accurately detect lung cancer, theoretically rejecting surgical biopsy. The USD market valued at 1.9 billion in 2022, with PET analysis winning the largest market share at 81.9%. Due to cumulative lung cancer prevalence globally, the PET scan market is estimated to observe tremendous growth.
  1. Tissue Sampling:
  • Biopsy - Implementing bronchoscopy or needle biopsies procedure involves taking a small specimen from the lymph nodes for biopsies, then using a microscope for viewing different kinds of tissue.
  • Sputum Cytology- Sputum from your cough may be taken and tested for the presence of cancer cells.
  • Blood Tests - Blood tests may be performed to gauge a person's general health, search for tumor markers (chemicals made by cancer cells) or monitor organ performance. Etc...

Below are the thrusts of the diagnostic industry, the market competitors who are changing healthcare with their progressive diagnostic inventions -

Diagnosis Market Players

Imaging Tests

Tissue Sampling

General Electric Company (GE Healthcare)

Roche Diagnostics

Siemens Healthineers

Abbott Laboratories

Philips Healthcare

Hologic, Inc.

Canon Medical Systems Corporation

Becton, Dickinson, and Company (BD)

Hitachi, Ltd.

Thermo Fisher Scientific, Inc.

Toshiba Corporation (Canon Medical Systems Corporation)

Danaher Corporation

Fujifilm Holdings Corporation (FUJIFILM Medical Systems)

Qiagen N.V.

Hologic, Inc.

Sysmex Corporation

Carestream Health, Inc.

Quest Diagnostics Incorporated

Esaote S.p.A.

Laboratory Corporation of America Holdings (LabCorp)

Shimadzu Corporation

Genomic Health, Inc.

Esaote S.p.A.

Biocept, Inc.

Samsung Medison Co., Ltd.

Guardant Health, Inc.

Mindray Medical International Limited

Biodesix, Inc

Neusoft Medical Systems Co., Ltd.

Foundation Medicine, Inc.

The below-mentioned state-of-the-art devices offer advanced capabilities and accuracy to enable the accurate and efficient detection of lung cancer.

Diagnosis Products

Imaging Tests

Tissue Sampling

Revolution™ CT


Optima™ CT


Discovery™ CT




SIGNA™ Pioneer


SIGNA™ Architect


Discovery™ PET/CT


VUE Point™ FX


Discovery™ MI



BD Vacutainer®


BD SurePath™


BD Vacutainer®







Lung Cancer Treatment Analysis

Unbridle the potential of DiseaseLandscape market research and consulting services to transform the treatment industry. With our extensive assessment of treatment modes, service contributions, product portfolios, and market players, we empower you to stay ahead of the competition. As a pledged partner to the pharmaceutical industry, we provide widespread assistance in planning, executing, and analyzing clinical trials for revolutionary new drug development.

In the market currently, several Treatment options are available.

  1. Surgery - Lung cancer surgery involves wedge resection, segmentectomy, lobectomy, or pneumonectomy.
  2. Radiation Therapy: Radiation therapy uses high-energy X-rays or other types of radiation to kill cancer cells or shrink tumours. It can be processed externally (external beam radiation therapy) or internally through radioactive materials placed near the tumour (brachytherapy).
  • External beam radiation therapy includes –

  • 3D Conformal Radiation Therapy
  • Intensity-Modulated Radiation Therapy (IMRT)
  • Image-Guided Radiation Therapy (IGRT)
  • Stereotactic Body Radiation Therapy (SBRT
  • Types of Brachytherapy –

  • High-Dose Rate (HDR) Brachytherapy
  • Low-Dose Rate (LDR) Brachytherapy

With the capacity to improve the quality of life for non-responsive cancer patients, radiation therapy bids a therapeutic approach for early-stage lung cancer patients who cannot undergo surgery. By openly targeting the tumor site, it seeks to reduce cancer cells and prevent local reappearance. Each year, millions of patients gain benefit from over 3.6 billion diagnostic radiology examinations, 37 million nuclear medicine procedures, and 7.5 million radiotherapy treatments, as reported by UNSCEAR.

Innovations in radiation technology are shoving the advancement of new treatment therapies and market players. GE Healthcare, a global leader, is altering healthcare with straightforward technologies, drug development, medical imaging, and diagnostics. Their advanced radiation therapy solutions showcased at ASTRO 2021 are shaping precision medicine and patient-centered care. With firm revenue growth, GE Healthcare dwarfs the market share with unconventional mammography devices, CT scanners, and compact ultrasounds.

Chemotherapy: Chemotherapy, directed in oral form, targets cancer cells to kill before, after, or as a primary treatment for radical or metastatic lung cancer before or after surgery. The deliverance of chemotherapy drugs is often done using ordinary medical devices, such as Infusion Pumps, IV Sets, Catheters, and Syringe Pumps. Most people receive chemotherapy depending on their NSCLC Lung cancer stage.

Targeted Therapy: Targeted therapy drugs target cancer cells with special proteins or mutations for growth and reduced side effects. The market for targeted therapy drugs in lung cancer has undergone substantial growth due to advancements in genomic profiling and increased insight into the molecular drivers of the disease. The market size is swayed by factors such as the dominance of lung cancer, the implementation of targeted therapy approaches, and the introduction of new targeted drugs.

Market leaders reshaping the landscape and driving innovation in the pursuit of improved health outcomes -

Treatment Market Players

Radiation Therapy

Targeted Therapy Drugs


Varian Medical Systems

Roche Holding AG

Becton, Dickinson and Company


Novartis AG

Terumo Corporation


Pfizer Inc.

Medtronic plc

Siemens Healthineers

Bristol Myers Squibb Company

Fresenius SE & Co. KGaA


Merck & Co., Inc.

Baxter International Inc.

Mitsubishi Electric Corporation

AstraZeneca PLC

Roche Holding AG

Hitachi, Ltd.

Johnson & Johnson

Siemens Healthineers

Mevion Medical Systems

Eli Lilly and Company

Thermo Fisher Scientific Inc.

ProTom International

Amgen Inc.

GE Healthcare

RaySearch Laboratories

Takeda Pharmaceutical Company Limited

Halyard Health, Inc.

Shinva Medical Instrument Co., Ltd.

AbbVie Inc.

Stryker Corporation

Brainlab AG

Gilead Sciences, Inc.

Elekta AB

Sumitomo Heavy Industries, Ltd.

Celgene Corporation

Accuray Incorporated

RefleXion Medical

Bayer AG

IBA (Ion Beam Applications)

Optivus Proton Therapy

Boehringer Ingelheim International GmbH

Hitachi, Ltd.

Theragenics Corporation

Daiichi Sankyo Company, Limited

Shinva Medical Instrument Co., Ltd.

C.R. Bard, Inc.

Astellas Pharma Inc.

Nordion (Canada) Inc.

Best Theratronics Ltd.

Biogen Inc.

Best Theratronics Ltd.

IsoRay Medical, Inc.

Sanofi SA

Varian Medical Systems

ION Beam Applications (IBA) Group

Vertex Pharmaceuticals Incorporated

Mevion Medical Systems


Treatment products

Brand name - Radiation therapy

Targeted Therapy Drugs



Erlotinib (Tarceva)

Alaris™ Pump module


Gefitinib (Iressa)

Alaris™ Syringe module


Afatinib (Gilotrif)

Alaris™ PC unit


Crizotinib (Xalkori)

BD Alaris™ Pump module set


Ceritinib (Zykadia)

BD Alaris™ Syringe module set


Alectinib (Alecensa)

BD Alaris™ gravity set


Brigatinib (Alunbrig)

BD Angiocath™


Crizotinib (Xalkori)

BD Insyte™


Entrectinib (Rozlytrek)

SIGMA Spectrum® Infusion System


Dabrafenib (Tafinlar) in combination with trametinib (Mekinist)

BD Introsyte™

MRIdian Cobalt

Crizotinib (Xalkori)

BD CareFusion™ Syringe pump

Siemens Artiste Linear Accelerator

Capmatinib (Tabrecta)

BD Plastipak™ Syringe pump

Siemens Primus Linear Accelerator

Selpercatinib (Retevmo)

BD Nexiva™


Larotrectinib (Vitrakvi)

BD Introsyte™


Entrectinib (Rozlytrek)

ARROW® Catheters

The mechanism of action of targeted drug therapy provides a better understanding of one of the Lung cancer treatment therapies.

Mechanism of action of Osimertinib for the treatment of non-small cell lung cancer –

Osimertinib is a targeted therapy drug for non-small cell lung cancer (NSCLC) with specific epidermal growth factor receptor (EGFR) mutations. It targets mutated EGFR protein, preventing uncontrolled growth and division, and selectively targets EGFR mutations like exon 19 deletion and L858R. Osimertinib also inhibits EGFR with the T790M mutation, making it a valuable treatment option for NSCLC patients with resistance to other EGFR TKIs. Osimertinib has shown significant efficacy in clinical trials and is approved for advanced or metastatic NSCLC with EGFR exon 19 deletion or L858R mutation, as well as patients with EGFR T790M mutation-positive NSCLC who have progressed on or after EGFR TKI therapy.

New Therapies in development –

Clinical development of cancer therapies, including cancer vaccines, CAR-T therapy, and HeSPs, aims to target cancer without limitations and overcome drug resistance and therapeutic failure.

Immunotherapy: Immunotherapy drugs accelerate the immune system to attack cancer cells, improving lung cancer treatment with immune frontier inhibitors like PD-1 and PD-L1. UCLA researchers found that pembrolizumab, an immunotherapy drug, improved NSCLC patients' survival rates from 5.5% to 15%.

Lung cancers benefit from immunotherapy, with an average response rate of 20-50%. As cancer research advances, oncologists believe that enduring responses may increase, enhancing outcomes for advanced bladder, kidney, and lung cancers. Clinical Trials are ongoing to explore immunotherapy combinations for lung cancer treatment.

Clinical trials assessment –

Disease Landscape Insights aids in planning and steering clinical trials for new drugs and therapies, patient recruitment strategies, regulatory compliance, safeguarding successful trial outcomes, etc.

The below table provides insights about ongoing clinical trials with their study titles and the phases in which they are being conducted –

Phase 1

Phase 2

Phase 3

Phase 4

Study of Niraparib in Combination with Osimertinib in EGFR-Mutated Advanced Lung Cancer

A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of VGT-309, a Tumor-Targeted, Activatable Fluorescent Imaging Agent, to Identify Cancer in Subjects Undergoing Lung Cancer Surgery

PARAT PAlliative RAdioTherapy to Lung Cancer a Randomized Multicentre Phase III Study

Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined with Cindilimab with Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer

LuCa-MERIT-1: First-in-human, Open Label, Phase I Dose Confirmation Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients with Advanced Non-small Cell Lung Cancer

68Ga-FAPI PET in Evaluation of the Patient with Known or Suspected Lung Cancer: Comparison with Standard 18F-FDG PET

Randomized Phase III Trial Investigating the Survival Benefit of Adding Thoracic Radiotherapy to Durvalumab (MEDI4736) Immunotherapy Plus Chemotherapy in Extensive Stage Small-cell Lung Cancer

Olanzapine as First Line Treatment for Prevention of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer: a Multicenter, Double-blind and Randomized Trial

Phase 1 Study of Combination Osimertinib, Platinum, Etoposide for Patients with Metastatic EGFR Mutant Lung Cancers with Concurrent RB1 and TP53 Alterations

A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer (DARES)

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Clinical Study of Chiauranib Capsule in Patients with Progressed or Relapsed Small-cell Lung Cancer After 2 Lines Chemotherapy (CHIS)

A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Durvalumab in Indian Adult Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (NSCLC)

Phase Ib Study to Test the Feasibility and Safety of a Personalized Vaccine in Combination with Low-dose Cyclophosphamide in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients with Lung Cancer (VELOCITY-Lung)

A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects with Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

Lorlatinib (PF-06463922) Continuation Protocol: An Open- Label, Single- Arm Continuation study for participants with ALK- Positivs or ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) continuing from Pfizer sponsored Lorlatinib Clinical studies

A Phase I, Open-label, Multicenter, Dose Escalation and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of PLB1004 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Trial of ZEN003694 in Squamous Cell Lung Cancer Patients Harboring NSD3 Amplification

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study

To Compare the Effects of Intraoperative Use of Intravenous Anesthetics Propofol and Inhaled Anesthetics Sevoflurane on the Prognosis of Patients Undergoing Surgery for Primary Lung Tumors and the Investigation of Its Mechanism of Action.

Amidst the ever-evolving topography of lung cancer, Disease Landscape Insights services serve as an important mediator in the expedition for expanded patient outcomes and revenue generation. Disease Landscape Insights services shed light on the latest advancements, treatment modalities, and emerging market trends, with clinical trial assistance, regulatory compliance, and product launch services shaping the future of lung cancer provision. With an emphasis on precision medicine, targeted therapies, and pioneering diagnostic attempts, the healthcare industries continue to make astonishing improvements toward branded and successful interventions.

Our all-inclusive analysis serves as a treasured resource for healthcare professionals, researchers, and industry stakeholders, facilitating informed decision-making and eventually flooring the way for a livelier future in lung cancer management, empowering market players to make informed decisions and driving impactful strategies and create value.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape